2022-RA-466-ESGO Long-term responders (LTR) to rucaparib in recurrent ovarian cancer: a sub-group analysis from the rucaparib access (RAP) program in Spain by GEICO
A. Yubero, Aránzazu Barquín, L. Gaba, B. Pajares, Piedad Reche, C. Salvador, J. Alarcón, L. Manso, R. Márquez, José Fuentes, J. Madani, Manuel Costenla, María Gutiérrez-Toribio, P. Estévez-García, A. Santaballa, L. Sánchez-Lorenzo, J. Calzas, A. Herrero, Á. Taus, A. González-Martín
{"title":"2022-RA-466-ESGO Long-term responders (LTR) to rucaparib in recurrent ovarian cancer: a sub-group analysis from the rucaparib access (RAP) program in Spain by GEICO","authors":"A. Yubero, Aránzazu Barquín, L. Gaba, B. Pajares, Piedad Reche, C. Salvador, J. Alarcón, L. Manso, R. Márquez, José Fuentes, J. Madani, Manuel Costenla, María Gutiérrez-Toribio, P. Estévez-García, A. Santaballa, L. Sánchez-Lorenzo, J. Calzas, A. Herrero, Á. Taus, A. González-Martín","doi":"10.1136/ijgc-2022-esgo.513","DOIUrl":null,"url":null,"abstract":"The proposed test is a viable alternative to the Myriad myChoice HRD test and can easily be implemented in a clinical laboratory for routine practice. The performance of the tests is similar in terms of hazard ratio but the lower failure rate of the Geneva HRD test allows a 10% increase in the number of patients receiving a conclusive laboratory result.","PeriodicalId":89343,"journal":{"name":"Clinical ovarian cancer and other gynecologic malignancies","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical ovarian cancer and other gynecologic malignancies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2022-esgo.513","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The proposed test is a viable alternative to the Myriad myChoice HRD test and can easily be implemented in a clinical laboratory for routine practice. The performance of the tests is similar in terms of hazard ratio but the lower failure rate of the Geneva HRD test allows a 10% increase in the number of patients receiving a conclusive laboratory result.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
